WO1996024381A3 - Kontrastmittelhaltige liposomen für die darstellung des intravasalraumes - Google Patents

Kontrastmittelhaltige liposomen für die darstellung des intravasalraumes Download PDF

Info

Publication number
WO1996024381A3
WO1996024381A3 PCT/EP1996/000539 EP9600539W WO9624381A3 WO 1996024381 A3 WO1996024381 A3 WO 1996024381A3 EP 9600539 W EP9600539 W EP 9600539W WO 9624381 A3 WO9624381 A3 WO 9624381A3
Authority
WO
WIPO (PCT)
Prior art keywords
blood pool
contrast media
liposomes containing
containing contrast
pool imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1996/000539
Other languages
English (en)
French (fr)
Other versions
WO1996024381A2 (de
Inventor
Andreas Sachse
Georg Roessling
Jens Leike
Werner Krause
Gabriele Schuhmann-Giampieri
Peter Muschick
Wolf-Ruediger Press
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Priority to JP8523999A priority Critical patent/JPH10513466A/ja
Priority to EP96904033A priority patent/EP0806969A2/de
Priority to AU47890/96A priority patent/AU4789096A/en
Publication of WO1996024381A2 publication Critical patent/WO1996024381A2/de
Publication of WO1996024381A3 publication Critical patent/WO1996024381A3/de
Priority to NO973666A priority patent/NO973666L/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Die Erfindung betrifft liposomale Kontrastmittelzubereitungen zur diagnostischen Darstellung des Intravasalraumes sowie deren Verwendung in der bildgebenden Diagnostik. Die Erfindung betrifft daher wirkstoffhaltige Liposomenformulierungen, dadurch gekennzeichnet, daß a) folgendes Mischungsverhältnis der Lipide vorliegt: 40-90 % Phospholipide oder Amphiphile, 10-50 % Sterole, 0-25 % Ladungsträger, b) die Liposomen einen mittleren Durchmesser von 100-400 nm aufweisen und c) der Wirkstoff ein Röntgen- oder MRI-Kontrastmittel oder ein Radiodiagnostikum ist.
PCT/EP1996/000539 1995-02-09 1996-02-09 Kontrastmittelhaltige liposomen für die darstellung des intravasalraumes Ceased WO1996024381A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP8523999A JPH10513466A (ja) 1995-02-09 1996-02-09 脈管内空間を視覚化するための造影剤を含むリポソーム
EP96904033A EP0806969A2 (de) 1995-02-09 1996-02-09 Kontrastmittelhaltige liposomen für die darstellung des intravasalraumes
AU47890/96A AU4789096A (en) 1995-02-09 1996-02-09 Liposomes containing contrast media for blood pool imaging
NO973666A NO973666L (no) 1995-02-09 1997-08-08 Kontrastmiddelholdige liposomer for avbildning av det intravaskulære rom

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19505813.5 1995-02-09
DE19505813 1995-02-09

Publications (2)

Publication Number Publication Date
WO1996024381A2 WO1996024381A2 (de) 1996-08-15
WO1996024381A3 true WO1996024381A3 (de) 1996-10-03

Family

ID=7754530

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/000539 Ceased WO1996024381A2 (de) 1995-02-09 1996-02-09 Kontrastmittelhaltige liposomen für die darstellung des intravasalraumes

Country Status (7)

Country Link
EP (1) EP0806969A2 (de)
JP (1) JPH10513466A (de)
AU (1) AU4789096A (de)
CA (1) CA2212162A1 (de)
DE (1) DE19606326A1 (de)
NO (1) NO973666L (de)
WO (1) WO1996024381A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19529922A1 (de) * 1995-08-01 1997-02-06 Schering Ag Verwendung von liposomalen Zubereitungen in der indirekten MRT-Lymphographie
GB9624918D0 (en) * 1996-11-29 1997-01-15 Nycomed Imaging As Particulate components
WO2001082977A1 (en) * 2000-04-28 2001-11-08 Fuji Photo Film Co., Ltd. Liposomes containing hydrophobic iodo compound
US7588751B2 (en) * 2004-07-21 2009-09-15 Konica Minolta Medical & Graphic, Inc. Liposome-containing radiographic contrast medium and preparation method thereof
JP5176320B2 (ja) * 2004-08-11 2013-04-03 コニカミノルタエムジー株式会社 リポソーム含有製剤の製造方法
EP2606912A1 (de) * 2011-12-23 2013-06-26 Central Medical Service Co., Ltd. Kontrastmittelzusammensetzung mit Kontrastverstärkungseffekt aufgrund des Umfassens eines hoch konzentrierten Mittels

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0179444A2 (de) * 1984-10-22 1986-04-30 Vestar, Inc. Verwendung eines Mittels mit chemotherapeutische Substanz einkapselnden Mizellteilchen für intravenöses Tumortargeting
WO1988001505A1 (en) * 1986-08-29 1988-03-10 The Government Of The United States Of America, As Scaled-up production of liposome-encapsulated hemoglobin
WO1990004943A1 (en) * 1988-11-09 1990-05-17 Unger Evan C Liposomal radiologic contrast agents
EP0405704A2 (de) * 1989-06-30 1991-01-02 Schering Aktiengesellschaft Derivatisierte DTPA-Komplexe, diese Verbindungen enthaltende pharmazeutische Mittel, ihre Verwendung und Verfahren zu deren Herstellung
WO1991005599A1 (de) * 1989-10-13 1991-05-02 Schering Aktiengesellschaft Berlin Und Bergkamen Verfahren zur herstellung von wässrigen dispersionen
WO1994008626A1 (de) * 1992-10-16 1994-04-28 Andreas Sachse Verfahren und vorrichtung zur herstellung flüssiger, disperser systeme
WO1994008565A1 (en) * 1992-10-14 1994-04-28 The Liposome Company, Inc. Interdigitation-fusion liposomes and gels
WO1995015153A1 (de) * 1993-12-02 1995-06-08 Schering Aktiengesellschaft Verfahren zur erhöhung der stabilität von hydrophile wirkstoffe enthaltenden liposomensuspensionen
DE4426438A1 (de) * 1994-07-26 1996-02-01 Schering Ag Verwendung von Chelaten als Röntgenkontrastmittel

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0179444A2 (de) * 1984-10-22 1986-04-30 Vestar, Inc. Verwendung eines Mittels mit chemotherapeutische Substanz einkapselnden Mizellteilchen für intravenöses Tumortargeting
WO1988001505A1 (en) * 1986-08-29 1988-03-10 The Government Of The United States Of America, As Scaled-up production of liposome-encapsulated hemoglobin
WO1990004943A1 (en) * 1988-11-09 1990-05-17 Unger Evan C Liposomal radiologic contrast agents
EP0405704A2 (de) * 1989-06-30 1991-01-02 Schering Aktiengesellschaft Derivatisierte DTPA-Komplexe, diese Verbindungen enthaltende pharmazeutische Mittel, ihre Verwendung und Verfahren zu deren Herstellung
WO1991005599A1 (de) * 1989-10-13 1991-05-02 Schering Aktiengesellschaft Berlin Und Bergkamen Verfahren zur herstellung von wässrigen dispersionen
WO1994008565A1 (en) * 1992-10-14 1994-04-28 The Liposome Company, Inc. Interdigitation-fusion liposomes and gels
WO1994008626A1 (de) * 1992-10-16 1994-04-28 Andreas Sachse Verfahren und vorrichtung zur herstellung flüssiger, disperser systeme
WO1995015153A1 (de) * 1993-12-02 1995-06-08 Schering Aktiengesellschaft Verfahren zur erhöhung der stabilität von hydrophile wirkstoffe enthaltenden liposomensuspensionen
DE4426438A1 (de) * 1994-07-26 1996-02-01 Schering Ag Verwendung von Chelaten als Röntgenkontrastmittel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAPELLIER M ET AL: "RADIOPAQUE LIPOSOMES FOR COMPUTED TOMOGRAPHY OPACIFICATION", CARDIOLOGY AND IMAGING, NEW ORLEANS, NOV. 4 - 7, 1988, vol. 10 PART 1/04, 4 November 1988 (1988-11-04), HARRIS G;WALKER C, pages 491 - 492, XP000093331 *

Also Published As

Publication number Publication date
JPH10513466A (ja) 1998-12-22
CA2212162A1 (en) 1996-08-15
AU4789096A (en) 1996-08-27
EP0806969A2 (de) 1997-11-19
WO1996024381A2 (de) 1996-08-15
NO973666L (no) 1997-10-08
DE19606326A1 (de) 1996-08-22
NO973666D0 (no) 1997-08-08

Similar Documents

Publication Publication Date Title
EP1158959B1 (de) Zusammensetzungen und verfahren zur verbesserten verabreichung hydrophober therapeutischer wirkstoffe
AU2076895A (en) Liposomes
CA2213861A1 (en) Method for loading lipid vesicles
Forssen et al. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors
US4920016A (en) Liposomes with enhanced circulation time
US5009819A (en) Taste moderating composition
IT8422357A1 (it) Metodo per la preparazione di composizioni aerosol, in particolare di aerosol liposomici
RU97102349A (ru) Композиция для получения лекарственного средства (варианты) и способ ее получения
AU608264B2 (en) Delivery vehicles with amphiphile-associated active ingredient
WO2001039744A3 (en) Radiation sensitive liposomes
NZ503568A (en) Biphasic lipid vesicle composition for transdermal administration of an immunogen
Buiting et al. Biodistribution of clodronate and liposomes used in the liposome mediated macrophage ‘suicide’approach
CA1333359C (en) Dental therapy by vesicle delivery
WO1996024381A3 (de) Kontrastmittelhaltige liposomen für die darstellung des intravasalraumes
CA2294448A1 (en) Pharmaceutical combination preparations containing erythropoietin and modified haemoglobins
EP0510086B1 (de) Interdigitation-fusionsliposomen und gele
WO2001082892A3 (de) Wirkstoffhaltige liposome
Utkhede et al. Effect of lipid dose on the redistribution and blood pool clearance kinetics of peg-modified technetium-labeled lipid vesicles
WO1998001124A3 (en) Pharmaceutical preparation containing nimesulide for topical use
Gregoriadis et al. Fate of liposomes in vivo: control leading to targeting
Hodis et al. In vivo hypertensive arterial wall uptake of radiolabeled liposomes.
CA2271735A1 (en) Magnetic resonance blood pool agents
AR002735A1 (es) Formulaciones liquidas de sustancias insecticidas activas.
EP0429442B1 (de) Zahnbehandlung durch freisetzung von vesikeln
Mazda et al. Preparation and characterisation of urea niosomes—

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN HU JP KR NO NZ SG US VN AZ BY KG KZ RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN HU JP KR NO NZ SG US VN AZ BY KG KZ RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996904033

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2212162

Country of ref document: CA

Ref country code: CA

Ref document number: 2212162

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1996 523999

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1996904033

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1998 875941

Date of ref document: 19980323

Kind code of ref document: A

Format of ref document f/p: F

WWW Wipo information: withdrawn in national office

Ref document number: 1996904033

Country of ref document: EP